Treatment timeliness and impact on survival in extensive stage small cell lung cancer.

Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/3237

Title:	Treatment timeliness and impact on survival in extensive stage small cell lung cancer.
Author:	Hiong, A. Robinson, J. Paul, E. Zeng, J. Tissera, S. Briggs, L. Faisal, Wasek Lesage, J. Wood, T. Torres, J. Underhill, C. Blum, R. Atkin, N. Caldecott, M. Richardson, G. Alexander, M. John, T. Bartlett, J. See, K. Parente, P. Parakh, S. Langton, D. Lyne, C. Irving, L. Harden, S. Zalcberg, J. Stirling, R.
Issue Date:	2025
Conference Name:	2025 World Conference on Lung Cancer
Conference Date:	September 6-9
Conference Place:	Barcelona, Spain
Abstract:	Rapid diagnosis and treatment initiation are widely viewed as key principles in the management of extensive-stage small cell lung cancer (ES-SCLC). The Australian Optimal Care Pathway (OCP) for lung cancer recommends confirmation of diagnosis within 2 weeks of initial specialist review and initiation of treatment within 6 weeks of specialist referral. The impact of adhering to these timeliness recommendations in the real-world setting is unknown.
URI:	http://hdl.handle.net/11054/3237
Internal ID Number:	03102
Health Subject:	SMALL CELL LUNG CANCER (SCLC) DIAGNOSTIC TIMELINESS TREATMENT INITIATION DELAY CLINICAL PRACTICE GUIDELINES
Type:	Conference Presentation
Appears in Collections:	Research Output

Files in This Item:

There are no files associated with this item.